FDA Approves GSK’s 5-in-1 Meningococcal Vaccine
On Feb. 14, 2025, British pharmaceutical and biotechnology company GSK plc announced that the U.S. Food and Drug Administration (FDA) approved its 5-in-1 meningococcal vaccine PENMENVY for licensure and use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of the bacterium Neisseria meningitidis (A, B, C, W, and Y), which […]
CDC Pushes Pfizer’s Pentavalent Meningococcal Vaccine
On Oct. 20, 2023, Pfizer, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its new pentavalent meningococcal vaccine, Penbraya, which targets five meningococcal serogroups (A, B, C, W and Y) that most commonly cause meningococcal disease in adolescents and young adults 10-25 years old. Penbraya, is recommended to be given in two […]